Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangxi Jimin Kexin Group is one of China's largest private pharmaceutical groups, with over 12,000 employees and annual revenues exceeding RMB 17.6 billion as of 2015. It operates across R&D, manufacturing, sales/distribution of pharmaceuticals (including both small molecules and biologics), with products exported internationally. The group has made significant investments through M&A to expand its footprint across China and abroad. Subsidiaries have engaged in licensing deals for innovative drug delivery technologies (e.g., NanoZolid®) targeting prostate cancer therapy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangxi Jimin Kexin Group.